Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors


March 15, 2022

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial


March 1, 2022

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board


January 19, 2022

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering


November 5, 2021

Cardiol Therapeutics Announces Pricing of Public Offering of Units


November 3, 2021

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units


November 2, 2021

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx™ for Acute Myocarditis


October 25, 2021

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx™, into Brazil, Mexico, and Canada


October 18, 2021

Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference


September 16, 2021

2025 Cardiol Therapeutics. All right reserved.